Summary: Pancytopenia occurring 1 year or later after allogeneic bone marrow transplantation typically prompts a primary consideration for relapse. We present the case of a 15-year old-girl who underwent transplantation for therapy-related myelodysplasia secondary to Ewing sarcoma treatment who developed pancytopenia with myelodysplasia 1 year after transplant due to copper deficiency. Copper deficiency is an important consideration in the evaluation of pancytopenia and myelodysplasia in pediatric patients.
C ytopenias may occur after for a variety of reasons after allogeneic bone marrow transplantation (BMT), including delayed engraftment, infections, marrow suppression secondary to medications, pure red cell aplasia due to ABO incompatible donors, thrombotic microangiopathy, and autoimmune etiologies. Infections, medications, and graft failure are all potential causes of pancytopenia; however, disease relapse remains the primary concern for new-onset pancytopenia occurring 1 year or later after allogeneic BMT. Copper deficiency is an important, reversible cause of pancytopenia and myelodysplasia that has predominantly been reported in older adult patients. We present the first reported case of pancytopenia with myelodysplasia due to copper deficiency after allogeneic BMT.
CASE REPORT
We report the case of a 15-year-old girl who underwent a 9/10 HLA-mismatched unrelated donor BMT for therapy-related myelodysplastic syndrome (MDS). She was diagnosed with nonmetastatic Ewing sarcoma of the left humerus 17 months prior and treated with limb-sparing surgery and chemotherapy that included a total of 3500 mg/m 2 of etoposide. Parents reported no administration of zinc or any other alternative medications during therapy. Bone marrow evaluation for prolonged thrombocytopenia after completion of sarcoma treatment revealed dysplastic changes in the erythroid series and megakaryocytes with an 11q23 chromosomal abnormality.
Conditioning therapy consisted of busulfan 4 mg/kg orally (PO) daily (total dose 16 mg/kg) in divided doses from day À 9 to À 6 with targeted pharmacokinetics and cyclophosphamide 50 mg/kg once daily intravenously (IV) (total dose 200 mg/kg) from days À 5 to À2. She received a total nucleated cell dose of 4.47Â 10 8 /kg. Graft-versus-host disease (GVHD) prophylaxis was cyclosporine 3 mg/kg/d from day À 2 and methotrexate 15 mg/m 2 IV on days +1 and 10 mg/m 2 IV on days +3, +6, and +11. Her course was complicated by idiopathic pneumonia syndrome requiring intubation, and she was treated with steroids and etanercept on Children's Oncology Group protocol ASCT0521. During her steroid taper, she developed grade II skin GVHD that was treated with topical steroids and narrow band UVB phototherapy. Neutrophil and platelet engraftment occurred at days +17 and +91, respectively. At 5 months after BMT, the patient was noted to have a low zinc level of 8.56 mmol/L and alkaline phosphatase level of 73 U/L (reference range, 85 to 380 U/L) and was placed on a 2-week course of zinc sulfate 200 mg PO daily. Repeat zinc level was normal (12.7 mmol/L), and the patient was instructed to discontinue the supplement. Additional complications included microangiopathic hemolytic anemia secondary to cyclosporine and left arm prosthesis failure requiring surgery.
Eleven months after transplant, she was noted to develop mild thrombocytopenia (40 to 50Â10 9 /L) from her maximum response after transplant (75 to 100Â 10 9 /L). The absolute neutrophil count was in the normal range at 1760Â 10 9 /L, but decreased from her maximum response after transplant (4180 to 7910Â10 9 /L). Medications included acyclovir, cetirizine, ergocalciferol, hydrocortisone, lansoprazole, morphine, ondansetron, oral contraceptives, potassium chloride, sertraline, trimethoprim/ sulfamethoxazole, and zolpidem. She had normal liver function, renal function, and thyroid function tests. Peripheral blood chimerism studies revealed 100% donor cells and fluorescence in situ hybridization (FISH) analysis for 11q23 was negative. Pentamidine was substituted for trimethoprim/sulfamethoxazole as Pneuocystis jiroveci pneumonia prophylaxis.
The following month she also developed anemia with hemoglobin in the range of 60 to 70 g/L requiring transfusion. Before transfusion, her peripheral blood smear revealed occasional anisocytosis. Her mean corpuscular volume and mean corpuscular hemoglobin were slightly elevated but stable after transplant at 100 fL and 31.8 pg/cell, respectively. She had normal levels of vitamin B 12 and red blood cell folate. Her bone marrow aspirate and biopsy at this time, 1 year after BMT, showed a hypocellular marrow with trilineage hematopoiesis and mild erythroid dysplasia, with a negative FISH analysis for 11q23, a normal comprehensive cytogenetic analysis, and chimerism studies remained 100% donor cells. Quantitative cytomegalovirus DNA polymerase chain reaction testing results were undetectable, with no other viral testing conducted. She had no signs or symptoms of chronic GVHD.
Two months later she also developed neutropenia of 670 Â10
9 /L, with unchanged results from peripheral blood chimerism studies and FISH analysis for 11q23. Renal and liver functions remained normal and red blood cell indices were stable. The following month the depth of her pancytopenia worsened, and a bone marrow aspirate and biopsy were repeated. She again had a hypocellular marrow with trilineage hematopoiesis; however, cytoplasmic vacuoles were noted in the myeloid and erythroid precursors (Fig. 1) . She had a negative FISH analysis for 11q23, a normal comprehensive cytogenetic analysis, and chimerism studies remained 100% donor cells. This morphologic finding was highly suggestive of zinc toxicity or copper deficiency. 1 Her zinc level was 53.6 mmol/L (reference range, 9.18 to 18.4 mmol/L), and her copper level was 1.89 mmol/L (reference range, 11.8 to 29.4 mmol/L).
After discovering the zinc toxicity and subsequent copper deficiency 15 months after BMT, the family admitted they had decided to continue the previous zinc supplement because they had read about the importance of zinc to support the immune system. The zinc sulfate was discontinued, and she was started on copper supplements 2 mg PO daily. Within 1 month, she had normalization of her peripheral blood counts as well as zinc and copper levels (18.2 and 22.9 mmol/L, respectively). A repeat marrow examination 4 months after receiving copper supplementation revealed trilineage hematopoiesis with no evidence of dysplasia or ring sideroblasts. Additional marrow evaluation at 2 years after transplant was also normal, and the patient remains in complete remission 4 years after BMT (Table 1) .
DISCUSSION
One prior pediatric series demonstrated that up to two thirds of transplant patients developed biochemical zinc deficiency, highly correlated with low alkaline phosphatase levels. 1 Zinc deficiency can cause symptoms of anorexia, negative nitrogen balance, weight loss, rash, and predisposition to infection, all of which are common complications of transplant itself and difficult to attribute to zinc deficiency alone. Because of the interactions of copper, zinc, and iron, it is important to balance the intakes of these minerals. 2 Both copper and zinc are absorbed in the stomach and proximal duodenum. Excessive levels of zinc can cause increased production of metallothionein in the enterocytes. Copper has a higher affinity for metallothionein than zinc; therefore, copper displaces zinc from metallothionein. When this displacement occurs, copper remains in the enterocytes that are sloughed off into the intestinal tract and eliminated, potentially leading to copper deficiency. 3 Copper is a cofactor for several key oxidative enzymes critical for appropriate iron transport and utilization. Copper and iron interact through ceruloplasmin, a plasma protein that not only delivers copper from the liver to peripheral tissues but also oxidizes ferrous iron. Once in its ferric form, iron is then able to bind transferrin for transport in circulation. 4 Hephaestin is a transmembrane copper-dependent ferroxidase in duodenal cells that plays a role with the interaction of copper and iron. 5 By oxidizing ferrous iron to the ferric state, iron can then be transported across the intestinal cells. If copper is deficient, defective iron utilization occurs that causes shortened red cell survival, due to changes in membrane fluidity and enhanced susceptibility to peroxidation. Furthermore, copper is also a cofactor for cytochrome c oxidase that is necessary for the reduction of iron to the ferrous form in the mitochondria. Without iron in the ferrous form, it cannot be properly incorporated into the protoporphyrin structure for hemoglobin synthesis. 6 Consequently, copper deficiency causes anemia by several mechanisms, including decreased iron absorption, transport, and incorporation into hemoglobin.
Copper deficiency also has been shown to cause neutropenia. Two theories that attempt to explain this occurrence include decreased survival of peripherally circulating granulocytes and arrested granulocyte maturation in the bone marrow. 4 Karimbakas et al 7 showed copper-deficient mice were leukopenic, with many granulocytes displaying an immature phenotype. Ly-6G is a murine marker for granulocyte maturity, and copper-deficient neutrophils expressed half the amount of Ly-6G. Ly-6G seems to be structurally related to the human molecule CD177, which promotes neutrophil migration across endothelial cells. 8 Although the mechanisms for neutropenia due to copper deficiency largely remain speculative, Peled et al 9 demonstrated an in vitro reduction in the differentiation rate of CD34 + stem cells in the setting of copper deficiency, which could represent the underlying reason for neutropenia.
Although our patient first presented with isolated thrombocytopenia, platelet counts are typically normal to mildly decreased in copper deficiency. 6 A prior adult series noted that only one of 8 patients had thrombocytopenia, described as mild. 4 From 2 pediatric reports of copper deficiency, 2 of the 4 patients were noted to have significant thrombocytopenia. These patients, however, also had notable liver disease that was likely the most significant contributing factor for thrombocytopenia. 10, 11 In addition, copper is essential for the function of several enzymes, including those required for infant growth, host defense mechanisms, cholesterol and glucose metabolism, myocardial contractility, and brain development. 2 Consequently, copper deficiency may also present with fractures, depigmentation of skin and hair, and neurological problems. 12 Pancytopenia and MDS due to copper deficiency are most commonly seen in patients on long-term total parenteral nutrition, gastrointestinal malabsorption (due to gastric surgery or inflammatory bowel disease), or excessive zinc supplementation. [12] [13] [14] Reversible MDS due to copper deficiency has been noted during the evaluation of adult patients referred for BMT. 4 Copper deficiency has significant hematologic affects that are easily reversible with adequate supplementation. The evaluation of a patient with pancytopenia or MDS either before BMT or after BMT should include copper deficiency in the differential diagnosis.
